Protagen
Oncimmune Buys Protagen for £4.1M
The company said that it plans to use Protagen's assets to further the development and commercialization of its EarlyCDT cancer diagnostics.
Protagen, NCT Heidelberg Partner to Predict Immunotherapy Response in Urothelial Cancer
The project aims to identify biomarkers for predicting response and adverse events in urothelial carcinoma patients receiving immunotherapy.
Protagen, NCT, NEC Partner on Prediction of Immunotherapy Response in Melanoma
The parties will use machine learning to develop biomarker models for immunotherapy endpoints, including adverse effects, clinical response, and survival.
With a series of recent collaborations in hand, the company is leveraging its experience in autoimmune biomarkers to move into the immunoncology space.
Protagen, Gustave Roussy Collaborating on Markers for Immunotherapy Side Effects
Under the collaboration, they will use Protagen's SeroTag platform to test cancer immunotherapy patients for markers linked to immune-related adverse events.
Jan 20, 2017
Aug 11, 2016
Protagen Licenses Systemic Sclerosis Marker to Inova
Nov 12, 2015
Protagen, Mikrogen Ink Lyme Disease Diagnostic Deal
Jun 24, 2015
Protagen Obtains ISO Certification
Dec 16, 2014
Protagen Closes First Part of Financing Round
Nov 21, 2014
Sep 5, 2014
Mar 16, 2012